Form 4: Neuraxis Director Jane Keyser Boosts Stake Amid Reporting Delay

Neuraxis Director Jane Keyser acquired 13,157 shares of common stock as compensation, increasing her direct beneficial ownership to 24,737 shares, though the transaction was reported with a significant delay.

Summary

• Jane Elizabeth Keyser, a Director of Neuraxis, INC (NRXS), acquired 13,157 shares of common stock.
• The transaction occurred on January 17, 2025, at a price of $2.85 per share.
• These shares were issued to Ms. Keyser as compensation for her services as an independent director of Neuraxis.
• Following this acquisition, Ms. Keyser directly beneficially owns a total of 24,737 shares of Neuraxis common stock.
• The Form 4 reporting this transaction was signed and filed on September 10, 2025, nearly eight months after the transaction date.

Sentiment

Score: 4

Explanation: While a director's acquisition of shares, even as compensation, can be a minor positive for aligning interests, the substantial delay of nearly eight months in filing this Form 4 (transaction in January 2025, filed in September 2025) is a serious regulatory compliance issue. This delay significantly detracts from any positive sentiment associated with the transaction itself.

Positives

• A director increasing their stake, even as compensation, can signal confidence in the company's future prospects.
• Issuance of shares as compensation helps align the director's financial interests with those of the company's shareholders.

Negatives

• The significant delay in filing the Form 4 (transaction on January 17, 2025, reported on September 10, 2025) raises concerns about regulatory compliance and internal controls.

Risks

• Potential regulatory scrutiny or penalties due to the substantial delay in filing the Form 4, which is typically required within two business days of the transaction.

Future Outlook

N/A

Industry Context

N/A

Related Party Transactions

• Issuance of 13,157 shares of common stock to Director Jane Elizabeth Keyser as compensation for services rendered to the Issuer.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to increased stock ownership. However, the significant delay in reporting the transaction raises concerns about corporate governance and transparency.
• Regulatory Authorities: The substantial delay in filing could lead to scrutiny or potential enforcement actions from the SEC.

Key Dates

Recommendation

While the director's acquisition of shares aligns her interests with shareholders, the significant delay of nearly eight months in filing this Form 4 (transaction on January 17, 2025, reported on September 10, 2025) is a serious regulatory compliance concern. This raises questions about the company's internal controls and adherence to SEC reporting requirements. Investors should exercise caution and monitor for further information regarding this compliance lapse. A 'hold' recommendation is appropriate given the mixed signals and the need for further investigation into the reporting delay.

Keywords

Neuraxis, NRXS, Insider Transaction, Director Stock Acquisition, Compensation, Form 4, Beneficial Ownership